We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A phase I trial of immunotherapy with intratumoral adenovirus-interferon-gamma (TG1041) in patients with malignant melanoma.
- Authors
Khorana, Alok A; Rosenblatt, J D; Sahasrabudhe, D M; Evans, T; Ladrigan, M; Marquis, D; Rosell, K; Whiteside, T; Phillippe, S; Acres, B; Slos, P; Squiban, P; Ross, M; Kendra, K
- Abstract
Interferon-gamma (IFN-gamma) has been shown to upregulate MHC class I and II expression, and to promote generation of specific antitumor immune responses. We hypothesized that intratumoral administration of an IFN-gamma gene transfer vector facilitates its enhanced local production and may activate effector cells locally. We conducted a phase I dose-escalation study of a replication-deficient adenovirus-interferon-gamma construct (TG1041) to determine safety and tolerability of intratumoral administration, in advanced or locally recurrent melanoma.
- Publication
Cancer gene therapy, 2003, Vol 10, Issue 4, p251
- ISSN
0929-1903
- Publication type
Journal Article
- DOI
10.1038/sj.cgt.7700568